menu

Special Report: Management Considerations and Unmet Needs in LGS and Dravet Syndrome

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Special Report: Management Considerations and Unmet Needs in LGS and Dravet Syndrome

4 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Lennox-Gastaut syndrome and Dravet syndrome are 2 rare epileptic disorders with a pediatric onset. They‘re often refractory to therapy and have significant side effects due to polytherapy. Listen in as Drs. Nilika Singhal, Elizabeth Thiele, and M. Scott Perry discuss treatment options and how you can lessen the impact of polypharmacy on your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Nilika Singhal, MD
    Pediatric Neurologist and Epilepsy Specialist
    UCSF Benioff Children’s Hospital
    Associate Professor
    UCSF Weill Institute for Neurosciences 
    San Francisco, CA 

    No relevant relationships reported.  

    Faculty:
    M. Scott Perry, MD
    Head of Neurosciences
    Jane and John Justin Institute for Mind Health
    Cook Children’s Medical Center
    Fort Worth, TX 

    Research: Encoded Therapeutics, Marinus, Stoke Therapeutics, Takeda Pharmaceuticals, and UCB Inc.
    Consulting Fees: Biocodex, BioMarin Pharmaceutical Inc., Bright Minds Biosciences, Marinus Pharmaceuticals, Inc., Neurelis Inc., Nobelpharma, Taysha Gene Therapies, and UCB Inc.

    Elizabeth A. Thiele, MD, PhD
    Director, Pediatric Epilepsy Program
    Massachusetts General Hospital
    Professor of Neurology
    Harvard Medical School
    Boston, MA

    Consulting Fees: Biocodex, Jazz Pharmaceuticals, LivaNova, Marinus Pharmaceuticals, Inc., Nobelpharma, Takeda Pharmaceuticals, and UCB Inc.

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Rosanne Strauss, PharmD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Outline strategies for recognizing and diagnosing Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS)
    • Identify FDA-approved treatments for LGS and DS and the seizure types for which they are effective and contraindicated
    • Review ongoing clinical trials in LGS and DS
    • Review the anti-seizure drugs (ASDs) used to treat LGS and DS and highlight the significant associated adverse effects, potential drug interactions, and monitoring requirements for each ASD
  • Target Audience

    This activity is designed to meet the educational needs of clinicians who treat patients with LGS and DS, including epileptologists, pediatric epileptologists, and neurologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Lennox-Gastaut syndrome and Dravet syndrome are 2 rare epileptic disorders with a pediatric onset. They‘re often refractory to therapy and have significant side effects due to polytherapy. Listen in as Drs. Nilika Singhal, Elizabeth Thiele, and M. Scott Perry discuss treatment options and how you can lessen the impact of polypharmacy on your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Nilika Singhal, MD
    Pediatric Neurologist and Epilepsy Specialist
    UCSF Benioff Children’s Hospital
    Associate Professor
    UCSF Weill Institute for Neurosciences 
    San Francisco, CA 

    No relevant relationships reported.  

    Faculty:
    M. Scott Perry, MD
    Head of Neurosciences
    Jane and John Justin Institute for Mind Health
    Cook Children’s Medical Center
    Fort Worth, TX 

    Research: Encoded Therapeutics, Marinus, Stoke Therapeutics, Takeda Pharmaceuticals, and UCB Inc.
    Consulting Fees: Biocodex, BioMarin Pharmaceutical Inc., Bright Minds Biosciences, Marinus Pharmaceuticals, Inc., Neurelis Inc., Nobelpharma, Taysha Gene Therapies, and UCB Inc.

    Elizabeth A. Thiele, MD, PhD
    Director, Pediatric Epilepsy Program
    Massachusetts General Hospital
    Professor of Neurology
    Harvard Medical School
    Boston, MA

    Consulting Fees: Biocodex, Jazz Pharmaceuticals, LivaNova, Marinus Pharmaceuticals, Inc., Nobelpharma, Takeda Pharmaceuticals, and UCB Inc.

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Rosanne Strauss, PharmD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Outline strategies for recognizing and diagnosing Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS)
    • Identify FDA-approved treatments for LGS and DS and the seizure types for which they are effective and contraindicated
    • Review ongoing clinical trials in LGS and DS
    • Review the anti-seizure drugs (ASDs) used to treat LGS and DS and highlight the significant associated adverse effects, potential drug interactions, and monitoring requirements for each ASD
  • Target Audience

    This activity is designed to meet the educational needs of clinicians who treat patients with LGS and DS, including epileptologists, pediatric epileptologists, and neurologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule29 Mar 2024